Skip to content

Haptoglobin and Iron in Parkinson's Disease

Haptoglobin Phenotype and Smoking: Effects on Iron Levels in Parkinson's Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02422992
Acronym
HPPD
Enrollment
342
Registered
2015-04-22
Start date
2013-02-28
Completion date
2016-06-30
Last updated
2016-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Iron metabolism, MRI, risk factors, haptoglobin phenotype

Brief summary

This is a case/control epidemiology study to identify what are the iron-metabolism abnormalities in Parkinson's disease (PD) patients, and risk factors relevant to PD predisposition.

Detailed description

A total of 342 participants, 100 PD patients and 242 age- and gender matched controls, were included in the study. All study participants were seen for one study visit in the morning at one of two Bastyr University Clinics in the Seattle area. Study participants were fasting at the time of the visit. During the study visit, participants donated a blood sample for the blood tests and complete an epidemiology questionnaire. A subset of 51 of the study participant who were seen for the visit at Bastyr University, underwent brain scan and Magnetic Resonance Imaging (MRI), at the University of Washington Department of Radiology. The MRI part of the study aims at estimating brain iron levels.

Interventions

None listed

Sponsors

University of Washington
CollaboratorOTHER
Bastyr University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
35 Years to 92 Years
Healthy volunteers
Yes

Inclusion criteria

for the Controls, for the blood draw and epidemiology visit: * Volunteers should be of age between 52 and 82 years of age, males of females.

Exclusion criteria

for the Controls: * presence of a neurodegenerative disease, * presence of active cancer under treatment, * HIV sero-positivity, Hepatitis B, C, of A sero-positivity * rheumatoid arthritis * recent blood donation (less than three months before the visit). * fever at the time of the visit Inclusion Criteria for the Parkinson's disease patients: Diagnosis of Parkinson's disease (UKBB clinical criteria).

Design outcomes

Primary

MeasureTime frameDescription
Iron metabolism differences between PD patients and controlsUp to 7 yearsIron metabolism will be measured by testing for serum iron and iron-binding proteins, and by estimating brain iron by MRI. Serum iron parameters that will be measured include total serum iron, iron-binding proteins such as transferrin and ferritin, and tests related to iron metabolism: transferrin % saturation, unsaturated iron binding capacity, soluble transferrin receptor, complete blood count, hemoglobin, uric acid, haptoglobin, haptoglobin phenotype. Differences in serum iron parameters, and brain iron levels, between PD patients and controls will be calculated.

Secondary

MeasureTime frameDescription
Environmental factors affecting PD risk and gene-environment interactionsrecruitment until January 2016Questionnaire data will be analyzed to identify risk factors for PD by comparing lifestyle and dietary patterns from questionnaire between PD cases and controls. Interaction between haptoglobin phenotype and tobacco smoking on PD risk will be calculated, as well as interaction between haptoglobin phenotype and environmental factors such as tobacco smoking and diet on serum iron and brain iron levels.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026